Chester County News and Community Website
BERWYN, PA — Panavance Therapeutics Inc. has shared promising interim findings from its ongoing Phase 1 clinical trial investigating misetionamide (GP-2250), a novel second-line therapy for advanced pancreatic cancer. These …
Panavance Therapeutics Reports Promising Phase 1 Results for Pancreatic Cancer Therapy Read More BERWYN, PA — Panavance Therapeutics Inc. has announced groundbreaking findings this week, demonstrating the potential of their investigational drug, misetionamide (GP-2250), to tackle various forms of cancer by directly inhibiting …
Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism Read More BERWYN, PA — Panavance Therapeutics Inc. announced interim results from its Phase 1 clinical trial at the 2024 Visceral Medicine Congress in Leipzig, Germany. The study evaluates the safety and efficacy …
Panavance Unveils Game-Changing Data: A New Hope for Pancreatic Cancer Patients? Read More BERWYN, PA — Panavance Therapeutics Inc. has announced the publication of encouraging data on misetionamide in the peer-reviewed journal, Cancer Medicine. The study conducted by Kim et al. at MD …
Panavance Therapeutics Reports Positive Data on Misetionamide in Ovarian Cancer Read More BERWYN, PA — Chester County-based biotech company, Panavance Therapeutics Inc., has announced the recent publication of positive data in the International Journal of Molecular Sciences about the anti-tumor activity of …
Panavance Therapeutics’ Cancer Drug Misetionamide Shows Promising Results in Melanoma Treatment Read More